ǰÑÔ
½ÇĤÐÂÉúѪ¹Ü(ehoroidal neovascularization,CNV)³£µ¼Ö½ÇĤ͸Ã÷¶È½µµÍ£¬ÊÇÖÂäµÄÒ»¸öÖ÷ÒªÔµ¹ÊÔÓÉ£¬Ò²ÊǽÇÄ¤ÒÆÖ²Êõºó±¬·¢ÇãÔþ·´Ó¦µÄ¸ßΣÒòËØ¡£ÁÙ´²ÉÏCNVÖÎÁÆÈÔÊÇ×ÊÖµÄÎÊÌâÖ®Ò»¡£CNV¶¯ÎïÄ£×ÓÊôÓÚÓÕ·¢ÐÔ¼²²¡¶¯ÎïÄ£×Ó£¬Í¨¹ýÎïÀíÒªÁ죨ÈÈÉÕÀÓÊõºÍ½ÇĤ·ìÏß·¨µÈ£©¡¢»¯Ñ§ÒªÁ죨¼îÐÔ»¯Ñ§Ò©ÎïÉÕÉ˵ȣ©¡¢ÉúÎïÒªÁ죨½ÇĤÄÒ´üÅжϷ¨£©ºÍÊÖÊõÒªÁ죨ÒìÖÖ½ÇÄ¤ÒÆÖ²¡¢½ÇĤ»ùÖÊÄÚ×¢ÉäÅ£ÇåÂѰס¢½ÇĤ»ùÖÊÖ×Áö×éÖ¯Ö²ÈëÊõµÈ£©¿ÉÈËΪµØÓÕ·¢¶¯ÎïµÄ½ÇĤÐÂÉúѪ¹ÜÔöÉú£¬±¬·¢ÀàËÆÓÚÈËÀ༲²¡µÄÄ£×Ó¡£ÏÂÃæÖ÷ÒªÏÈÈݽÇĤÐÂÉúѪ¹ÜÑо¿×î³£ÓõÄÒªÁì——½ÇĤÄÒ´üÅжϷ¨¡£³£ÓõÄÓÕµ¼¼ÁÓÐÄÚ¶¾ËØ¡¢¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×Ó(basic fibroblast growth factor, bFGF)¡¢Ñª¹ÜÄÚÆ¤Éú³¤Òò×Ó(vascular endothelial growth factor, VEGF)¡¢¶þÑõ»¯¹èµÈ£¬ÒÔ»ºÊÍÄÚ¶¾ËغÍbFGF»ºÊÍÒ©ÍèÓÕÉú½ÇĤÐÂÉúѪ¹Ü¶¯ÎïÄ£×ÓµÄÖÆ×÷ΪÀý£¬¾ÙÐмòÆÓÏÈÈÝ¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎʵÑ鶯Îï
¡¾ÔìÄ£»úÖÆ¡¿£º
ÄÚ¶¾ËØÓÕÉúµÄCNV¼Ì·¢ÓÚÑ×Ö¢·´Ó¦£¬²¢ÇÒÑ×Ö¢´Ì¼¤·´Ó¦ÓëÐÂÉúѪ¹ÜµÄÓÕÉú³ÊÕýÏà¹Ø£¬ÄÚ¶¾ËØÓÕÉúÐÂÉúѪ¹ÜÀú³Ì¿ÉÄÜÊܾÞÊÉϸ°ûÉøÍ¸µÄbFGFÒò×Óµ÷¿Ø£¬²¢ÇÒ±»¾ÞÊÉϸ°ûÉøÍ¸µÄÆäËûÒò×ÓÈçÖ×Áö»µËÀÒò×Ó-αºÍת»¯Éú³¤Òò×Ó-β·Å´ó¡£
bFGFÊǰüÀ¨146¸ö°±»ùËá¾ßÓÐÖØ´ó¹¦Ð§µÄµ¥Á´·ô£¬ÔÚһϵÁÐÌåÍâʵÑéÖУ¬±»Ö¤Êµ¾ßÓжÔѪ¹ÜÄÚÆ¤Ï¸°û·Ö½â¡¢ÔöÖ³¡¢Ç¨áãºÍÇ÷»¯×÷Óá£bFGFÓÕµ¼µÄ΢Ѫ¹ÜÄÚÆ¤Ï¸°û¿É±¬·¢´ó×ڵĵ-PA£¬ÔÚѪ¹ÜÌìÉúÔçÆÚÆðÖÐÐÄ×÷Ó㬵-PA½«ÏËάÂѰ×ÈÜøÔת»¯³É¾ßÓÐø»îÐÔµÄÏËάÂѰ×ÈÜø£¬ºóÕßÓֿɼ¤»î½ºÔø£¬ÏûÈÚÐÂÉúѪ¹ÜÆðʼԵµÄ»ùĤ£¬²¢µ¼ÖÂÄÚÆ¤Ï¸°û½øÈëÈýάµÄ½ºÔ»ùÖÊ£¬ÐγÉеÄëϸѪ¹ÜÑ¿¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
»ºÊÍÄÚ¶¾ËؾۺÏÎïÒ©ÍèµÄÖÆ±¸£ºÒÒÏ©£´×Ëá£ÒÒϩ֬¾ÛºÏÎï(Elvax)Öé½ÓÄɸߴ¿µÄ¼ºÈ©Ï´åªÖÁ·Ö¹â¹â¶È´¿£¬ÔÚÊÒÎÂϽ«¾ÛºÏÎïÈÜÓÚ¶þÂȼ×ÍéÖÁ10£¥(W/N)×îÖÕŨ¶È£¬½«Ò»¶¨±ÈÀýE.ColiÄÚ¶¾ËØÓë10£¥Elvax»ìÏý²¢Ç¿Á¦½Á°èÖÁÔȳÆÐüÒº¡£ÄÚ¶¾ËØ£ElvaxÐüÒºÓÃÏû¶¾µÎ¹ÜµÎÈë8¿×²£Á§°å¾ÛºÏ£¬ÍêÈ«¾ÛºÏºó£¬ÖƳÉ1mm3¾Þϸ£¬£¨1.3±0.3)mg/Í裬×ÏÍâÏßÏû¶¾ºó-40¡æÔ̲ر¸Óá£
bFBF»ºÊÍÒ©ÍèµÄÖÆ±¸£ºbFBF»ºÊÍÒ©ÍèÓÉ»ºÊͼÁ¾Û¼×»ù±ûÏ©Ëá£2£ôÇÒÒõ¥(Hydron)ºÍÒ»¶¨Á¿µÄÓÕµ¼¼ÁbFGF»ìÏý¶ø³É£¬ÔÚbFGF-Hydron»ºÊÍÒ©ÍèÖмÓÈëÒ»¶¨Á¿µÄÁòÌÇÂÁ(sucralfate)£¬ÖƳÉHydron°ü¹üµÄbFGF-sucralfate»ºÊÍÒ©Í裬¿ÉÓÐÓõØÎȹÌbFGFµÄÉúÎï»îÐÔ£¬¼õ»ºbFGFµÄÊÍ·Å¡£
½ÇĤÄÒ´üÖÆ×÷£ºËùÓÐÊÖÊõ°ì·¨¾ùÔÚÎÞ¾úÌõ¼þϾÙÐУ¬3£¥Îì°Í±ÈÍ×ÄÆÍöúÔµ¾²Âö×¢ÉäÈ«ÉíÂé×í(25mg/kg), 1£¥µØ¿¨Òò¾Ö²¿µãÑÛÂé×í£¬ÔÚ½ÇĤÖÐÑë×÷1.5mm¡¢1/2½ÇĤºñ¶ÈÇпڣ¬Ïò6µãλDZÐÐÊèÉ¢1/2ºñ½ÇĤÄÒ´ü£¬ÖÁ¾à½ÇĤԵ2.0mm´¦£¬½ÓÄɲ£Á§Ì×¹ÜÖ²ÈëÖÆ±¸ºÃµÄ»ºÊÍÒ©Í裬½«ÄÒ´üÇпÚÖØÐ¸´Î»£¬ÒÔ±ãÓúºÏ¡£
¡¾Ä£×ÓÌØµã¡¿£º
CNVÓë¾Ö²¿ÄÚ¶¾ËسʼÁЧÒÀÀµ¹ØÏµ¡£ÓÃŨ¶ÈΪ15£¥ÄÚ¶¾ËؾۺÏÎïÄÜ»ñµÃÏÔÖøµÄ½ÇĤÐÂÉúѪ¹ÜÉú³¤£¬½ö°éÓÐÉÔ΢µÄ½ÇĤˮÖ×£¬ÄÜÓÕÉúÏàÒ˵ÄCNV¶¯ÎïÄ£×Ó£¬ÄÚ¶¾ËØÅ¨¶È¹ý¸ßÔòÒýÆðÏÔÖøµÄ½ÇĤÑ×Ö¢£¬»ùÖÊ»ì×Dz¢ÇÒÐÂÉúѪ¹ÜÉú³¤Ò×Èںϣ¬Ó°ÏìÐÂÉúѪ¹ÜÕÉÁ¿ºÍÅÌËãµÄ׼ȷÐÔ£¬Å¨¶ÈÌ«µÍÔòÓÕµ¼Á¦¶È¹ýС£¬²»ÊʺÏÄ£×ÓµÄÒªÇó¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
»ºÊÍÄÚ¶¾ËؾۺÏÎïÒ©ÍèÓÕÉúCNVÄ£×ÓµÄÓŵãÊÇ£ºÐÂÉúѪ¹Ü¶¨Ïò³ÉÊøÉú³¤£¬ ÖØ¸´Îȹ̣¬²â¶¨ºÍ¶¨Á¿ÆÊÎöµÄ׼ȷÐÔÏÔ×ÅÌá¸ß£¬²¢ÇҿɽÓÄÉÅÌËã»úͼÏñÆÊÎöϵͳ¾ÙÐÐÖðÈÕÒ»Á¬¶¯Ì¬¶¨Á¿²â¶¨£¬Àû±ãÓë±ÈÕÕ×é½ÏÁ¿¡£
bFGF»ºÊÍÒ©ÍèÓÕÉúµÄCNV¶¯ÎïÄ£×ÓµÄÓŵãÔÚÓÚ£ºbFGF×÷ΪÐÂÉúѪ¹ÜµÄÖ±½Ó´Ì¼¤Òò×Ó£¬¿Éɨ³ýÑ×Ö¢µÈ¼ä½ÓÐÂÉúѪ¹Ü´Ì¼¤ÒòËØ£¬Õâ¹ØÓÚÌØ¶¨µÄÐÂÉúѪ¹ÜÒÖÖÆ¼ÁµÄÁÆÐ§ÆÀ¼ÛÓÐÖ÷ÒªÒâÒ壻±ãÓÚ¶¨Á¿ÆÊÎö£»ÎȹÌÐÔºÍÖØ¸´ÐÔ¾ã¼ÑÇÒ¾¼ÃÊÊÓá£
²Î¿¼ÎÄÏ×£º
1.ÇñÅàèª. ½ÇĤÐÂÉúѪ¹ÜµÄ¶¯ÎïÄ£×Ó£®ÍâÑóҽѧ£ºÑÛ¿ÆÑ§·Ö²á£¬2000, 24 (6):360-363
2.ºú¶«¶«£¬Íõ¼ÎÈÝ£¬ÑîÔÚ¸»£®¼¤¹âÑÛËðÉ˶¯ÎïУÐÍÑо¿Ï£Íû£®¾üÊÂҽѧ¿ÆÑ§ÔºÔº¿¯£¬2010,5:489-491
3.Äô°®ÇÛ£¬Ï¯Ã磬ϯÐË»ª£¬µÈ´¿´â°ÌÕ¶¾ÐÔ½ÇĤÑ×¢òÊóÄ£×ӵĽ¨Éè¼°ÅжϹú¼ÊÑÛ¿ÆÔÓÖ¾£¬2012,12(11): 2059-2061
4.ÐìÑÒ±äÓ¦ÐÔ½áĤÑ×¶¯ÎïÄ£×ÓÑÛ¿ÆÑо¿£¬2001, 19(2):181-183
5.κÈ𻪣¬ºÂÓÀÄÈ£¬ÕÔÉÙÕ꣮×ÔÉíÃâÒßÏà¹ØÐÔ¸ÉÑÛ¶¯ÎïÄ£×ÓµÄÑо¿Ï£Íû£®ÑÛ¿ÆÐÂÏ£Íû£¬2012, 32 (7):690-693
6.Calonge MC, Pastor JC, Herreras JM, el al. Pharmacologic modulation of vascular permeability in ocular allergy in the rat. Invest Ophthalmol Vis Sci, 1990, 31 (1): 176-180
7.Marquart ME.Animal models of bacterial keratitis.J Biomed Biotechnol,2011,2011:680642
8.Pavan-Langston D. Herpes simplex virus ocular infections:current concepts of acute, latent and reactivated disease. Trans Am Ophthalmol Soc, 1990,88:727-796